

2023

2023 8

11 —

—

1		
2		
3		
4		2023
5		2023
6		
7		

--	--	--

2023

50%

“

”

/

“ ”


“ ”

2023

2023

	2023	2022	%	2021
	100,711.89	645,035.66	-84.39	451,453.93
	36,372.11	193,680.05	-81.22	224,269.64
	7,164.94	183,451.93	-96.09	215,054.46
	4,353.96	255,894.69	-98.30	187,707.06

	2023	2022		2021
			%	
	720,127.10	750,061.65	-3.99	636,890.71
	845,420.50	917,376.21	-7.84	709,037.01



10

100

200

“ ”

“ ”

“

”

IVD

160

“

"

“

"

“

"

“

+

"

“

"

“

"

“2

24

48

"

“

"

/

“

"

2023

2023	23,564.04	2022	30.11%
	23.40%	2022	1.58%
			15.13

[illegible]

								200	1	,
								1		
								100		
								HBV	HCV	HIV
								HPVDNA		
								1	4.5	3-5
								HPV		65
								2023-2030	40%	2025
								50%	2030	
								70%	2023	
								HPV		
								HPV		
					3		3		HPV	
4		12,800.00	1,525.42	8,991.19		1				
								100	WHO	3.7
								4		
								7	50%	
										50
								PCR		

5		6,600.00	349.76	3,903.63	CE ² 3	1 CE ²		7,000 Polaris	/ HCV	1,000 25%	HBV 2020 17%	2030
								30%	9%	80%		
								90%	2030			
								2021-2030				
6		15,000.00	3,599.66	10,605.34	SansureSeq1000			2020 2025		341	5	149
								18%				

					6			
					1			
	/	145,000.00	23,564.04	94,068.16	/	/	/	/

2023 12 31	
	1,869,269,811.32
	1,645,056,867.17
	269,873,051.63
	104,945,715.54
	100,238,100.00
	1,170,000,000.00
	12,707,865.13
	9,899,500,000.00
	9,659,500,000.00
	77,524,486.05
2023 12 31	74,445,295.33

2023

2023 8

2 —

2022

		19,004.23	19,004.23	-	-
		25.77	25.77	-	-
		25.77	25.77	-	-
		15.49	15.49	-	-
		11.79	11.79	-	-
		20.22	20.22	-	-
		0.23	0.23	-	-
		7.96	7.96	-	-
		16.50	16.50	-	-
		7.40	7.40	-	-
		7.58	7.58	-	-
		5.55	5.55	-	-
		3.89	3.89	-	-

		3,437.92	5.84%	-
		59.03	0.10%	
		60.65	0.10%	
		10.92	0.02%	
		16.98	0.03%	
		18.19	0.03%	

		60.65	0.10%	
		60.65	0.10%	
		40.43	0.07%	
		29.11		
		24.26		
		30.32		

2023 12 31

2023

(本页无正文,为《西部证券股份有限公司关于星霜生物科技股份有限公司 2023 年度持续督导报告》之盖章页)

